Innovation Pharmaceuticals Inc (IPIX)

[georgejjl]

Clinical Remission in > 50% subjects (Day 42)
Similar across cohorts
• 60% Cohort A (3 of 5)
• 67% Cohort B (4 of 6)
• 75% Cohort C (3 of 4)
Analysis population: Includes subjects with Endoscopy, Rectal Bleeding and Stool Frequency subscores at baseline and Day 42; one subject in Cohort A and one subject in Cohort C are not included due to no Day 42 endoscopy (subjects declined)


Rectal Bleeding (RB) subscore
• Improved for all subjects, all cohorts
• No rectal bleeding (RB=0) at Day 42
• 5 of 6 subjects Cohort A
• All 6 subjects Cohort B
• All 5 subjects Cohort C


Improvement in Quality-of-Life (QoL)
(reported by 16 /17 subjects after 6 wks treatment)
• QoL instrument
• Short Inflammatory Bowel Disease Questionnaire [SIBDQ]
• 10 pt change SIBDQ clinically important
• At Day 42
• More than 60% subjects in each cohort achieved ≥10-point or more improvement
• At least half of subjects in cohorts B and C also showed ≥20-point or more improvement
• >50-point improvement observed for one subject in Cohort B

https://static1.squarespace.com/static/5715352e20c647639137f992/t/5beac1250ebbe846eb4b031e/1542111528589/IPI+IBD+Innovate+2018+Poster+%28final%29.pdf

Good luck and GOD bless,

George